Sandoz

Contact
sandoz.com
+4980244762595

Sandoz International GmbH

Industriestrasse 25
83607 Holzkirchen
Germany
+4980244762595
sandoz.com
Contact
Profile Products News
Contact

About Sandoz

Sandoz is a global leader in generic pharmaceuticals and biosimilars.

As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people's lives. We contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine.

Our global portfolio comprises approximately 1,000 molecules, covering all major therapeutic areas, which accounted for 2019 sales of USD 9.7 billion. Our products reach more than 500 million patients.

Read more about Sandoz
Facts about Sandoz
  • Focus : Manufacturer
  • Employees: 10,001+
  • Industry : Pharma

Product portfolio of Sandoz

Product portfolio

Show all

News about Sandoz

Sandoz

29-Jul-2020 | business & finance

Sandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in Europe

Sandoz, the Novartis generics and biosimilars division, is pleased to announce plans for a joint investment, together with the Austrian federal government ...

Read news
Sandoz

14-Mar-2019 | people

Novartis announces change in Sandoz leadership

Novartis announced that Richard Francis will be stepping down as CEO of Sandoz, a Novartis division, and as a member of the Executive Committee of Novartis ...

Read news
Sandoz

20-Jan-2012 | research and development

Sandoz initiates two more Phase III biosimilar trials

Sandoz announced that it has initiated two milestone Phase III clinical trials - one for biosimilar filgrastim (Amgen's Neupogen®) in the US market, the ...

Read news
Sandoz

14-Jan-2011 | research and development

Sandoz announces phase II clinical trial for biosimilar version of leading monoclonal antibody rituximab

Sandoz announced that it has begun a phase II clinical trial in patients for biosimilar rituximab (Roche's Rituxan® / Mabthera®), a monoclonal antibody ...

Read news
Sandoz

27-Jul-2010 | research and development

Sandoz leads the way with first generic version of 'gold standard' anti-thrombotic Lovenox

Sandoz announced the introduction of enoxaparin sodium injection, the first generic version of Lovenox®, in the US. Product shipment began immediately ...

Read news
Sandoz

25-Sep-2009 | business & finance

Sandoz completes acquisition of EBEWE Pharma, improving global patient access to affordable injectable cancer medicines

Sandoz to focus on quick and seamless integration for customers and employees

Read news
Sandoz

08-Sep-2009 | politics & laws

Orion and Hospira,Inc. sue Sandoz companies in the U.S. to enforce their U.S. Patents covering the proprietary drug Precedex

Orion Corporation and Hospira, Inc. filed together a patent infringement lawsuit in the United States to enforce Orion's U.S. Patent No.4,910,214 and Orion ...

Read news
Sandoz

26-Jun-2009 | research and development

Sandoz receives approval for first-ever Japanese biosimilar

Sandoz receives approval for first-ever Japanese biosimilar, recombinant human growth hormone somatropin, further reinforcing global pioneer position in field

Read news
Show more news about Sandoz

Here you will find Sandoz International GmbH